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Abstract
Background: Radiation-induced nephropathy is still dose limiting in radionuclide therapy of neuroendocrine
tumors. We investigated the nephroprotective potential of the angiotensine converting enzyme inhibiting drug enalpril
after [177Lu]-DOTATATE therapy in a murine model of radiation-induced nephropathy by renal scintigraphy.
At first, the appropriate therapy activity to induce nephropathy was identified. Baseline scintigraphy (n = 12) entailed
12-min dynamic acquisitions after injection of 25 MBq [99mTc]-MAG3, which was followed by radionuclide therapy
at four escalating activities of [177Lu]-DOTATATE: group (Gp) 1: 10 MBq; Gp 2: 20 MBq; Gp 3: 40 MBq; Gp 4:
65 MBq. Follow-up [99mTc]-MAG3 scintigraphy was carried out at days 9, 23, 44, and 65. The treatment activity
for the intervention arm was selected on the basis of histological examination and declining renal function. In the
second part, daily administration by gavage of 10 mg/kg/d enalapril or water (control group) was initiated on the
day of radionuclide therapy. Follow-up scintigraphy was carried out at days 9, 23, 44, 65, and 86. We also created
a non-therapy control group to detect therapy-independent changes of renal function over time. For all scintigraphies,
mean renogram curves were analyzed and the “fractional uptake rate” (FUR; %I.D./min ± SEM) of the tracer by
the kidneys was calculated as an index of renal clearance.
Results: At day 65 of follow-up, no significant change in the FUR relative to baseline (11.0 ± 0.3) was evident
in radionuclide therapy groups 1 (11.2 ± 0.5) and 2 (10.1 ± 0.6), but FUR was significantly reduced in groups 3
(8.93 ± 0.6, p < 0.05) and 4 (6.0 ± 0.8, p < 0.01); we chose 40 MBq [177Lu]-DOTATATE (Gp 3) for the intervention
study. Here, at the last day of follow-up (day 86), FUR was unaltered in enalapril-treated mice (11.8 ± 0.5) relative to the
baseline group (12.4 ± 0.3) and non-therapy group (11.9 ± 0.8), whereas FUR in the control group had undergone
a significant decline (9.3 ± 0.5; p < 0.01). Histological examination revealed prevention of kidney damage by
enalapril treatment.
Conclusions: Treatment with enalapril is effective for nephroprotection during radionuclide therapy with
[177Lu]-DOTATATE in mice. Although these results are only limitedly transferable to human studies, enalapril
might serve as a promising drug in the mitigation of nephropathy following treatment with [177Lu]-DOTATATE.
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Background
Peptide receptor radionuclide therapy (PRRT) with
[Y-90-DOTA0,TYR3]-octreotide ([90Y]-DOTATOC) and
[177Lu-DOTA0,TYR3]-octreotate ([177Lu]-DOTATATE)
has emerged as a well-established therapy option in the
treatment of inoperable or metastasized neuroendocrine
tumors (NET) expressing somatostatin receptors [1, 2]. As
reported in several studies, PRRT yields encouraging
results with respect to favorable response rates and
progression-free survival [1–8]. However, an important
factor limiting benefits of this therapy is the occurrence of
radiation-induced nephropathy, which arises due to renal
clearance and megalin-receptor mediated tubular re-
absorption of the chelated somatostatin analogues [9, 10].
Significant impairment in renal function has been re-
ported both in clinical and in pre-clinical surveys [11–17].
There are various pharmacological strategies to decrease
renal radiation exposure, for instance inhibiting tubular
reabsorption. The co-administration of positively charged
amino-acids, mainly arginine and lysine, reduces renal up-
take of radiolabeled somatostatin analogues both in ani-
mal studies [16, 18] and in patient studies [19, 20].
Histopathological findings in kidneys after PRRT present a
pattern of tubular and glomerular damage which seems
similar to that evoked by external beam radiation [21].
The renin-angiotensin-aldosterone-system (RAAS) is
also decisively implicated in the pathogenesis of radiation-
induced nephropathy [21, 22]. RAAS-modifying phar-
macotherapies have been ascertained for the reduction
of renal damage after radiation in animal models. The
nephroprotective potential of angiotensin-converting-
enzyme (ACE) inhibitors after external beam radiation
of the kidneys in rats was first reported by Cohen et
al. in 1992 [23]. The mitigative effects of ACE inhibitors
were confirmed in further pre-clinical experiments by the
same and other research groups [24, 25], as well as in
humans by Moll et al. [12].
Given the similar pathologies and histopathological
changes, we hypothesized that the pharmacological
treatments effective in nephrotoxity induced by external
beam radiation might also mitigate [177Lu]-DOTATATE
induced nephrotoxicity.
Methods
Animals and experimental design
All animal experiments were conducted in accordance
with institutional guidelines and approved by the ethics
committee and Administrative Panel on Laboratory
Animal Care (Government of Upper Bavaria, Germany;
reference number 55.2-1-54-2531-136-09). We used fe-
male Balb C mice, aged 10 weeks and weighing 20 to 24 g
(Charles River Laboratories, Sulzfeld, Germany), which
were fed a standard diet and given free access to water.
No-carrier added lutetium-177 was obtained from
Isotope Technologies Garching GmbH (Garching,
Germany). DOTA0,TYR3-octreotate was obtained from
ABX advanced biochemical compounds (Dresden,
Germany). Radiolabeling was performed according to a
previously described protocol [26, 27]. Other pharmaceu-
ticals were obtained from Sigma-Aldrich (Taufkirchen,
Germany).
The study consisted of two parts. In the first part,
we investigated the activity-dependent impairment of
renal function in mice treated with four activities of
[177Lu]-DOTATATE: group 1 (n = 6), 10 MBq; group
2 (n = 8), 20 MBq; group 3 (n = 7), 40 MBq, and
group 4 (n = 7), 65 MBq. PRRT was carried out at
day 2. [177Lu]-DOTATATE was injected via the tail
vein. Follow-up scintigraphies to assess renal function
were carried out at days 9, 23, 44, and 65.
In the second part of the study, the nephroprotective
properties of enalapril were evaluated in mice (n = 7)
treated with 40 MBq [177Lu]-DOTATATE, as selected
in part one. PRRT was performed under anesthesia as
described above. Enalapril was administered by gavage
on the day of radionuclide therapy, and daily thereafter
until the end of the study. The pharmaceutical dose
(10 mg/kg) was chosen in accordance with previously
published studies [28]. Control mice (n = 7) received
daily gavage with sterile water. Furthermore, we created
a third group of (n = 7) mice, which served as a non-
therapy control. In this group, no PRRT was carried out
and mice received MAG3 scintigraphy to identify
therapy-independent changes in renal function over
3 months in healthy mice.
MAG3 scintigraphy was obtained at baseline in order
to determine the renal function prior to PRRT. Follow-
up renal scintigraphies to assess renal function were car-
ried out in all mice at days 9, 23, 44, 65, and 86.
Renal scintigraphy
MAG3 scintigraphy (Technescan MAG3, Covidien,
Neustadt/Donau, Germany) was performed as previously
described [29–31]. After the induction of anesthesia with
a combination of ketamine (75 mg/kg, i.p.) and medeto-
midine (1 mg/kg, i.p.), mice were placed on a thermo-
statically heated pad to maintain body temperature close
to 37 °C. Mice received a standard activity of 25 MBq
[99mTc]-MAG3 administered in 150 μl saline as a bolus
via a tail vein. Whole body scintigraphic recordings
using one head of a triple-headed gamma camera
(Philips—former Picker—Prism 3000 XP, Cleveland, USA)
equipped with a LEHR collimator were initiated upon
tracer administration. The dynamic planar acquisitions
consisted of 144 frames of 5 s each, to a total of 12 min.
The image magnification was set to four times.
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Image files were analyzed using Hermes Dynamic Study
display software V4.0 (Hermes Gold V2.10, Hermes
Medical Solutions, Stockholm/London). Standard region
of interest (ROI) were applied to the whole body, both
kidneys, peri-renal background reference regions, bladder,
blood pool in the heart, and the site of injection (Fig. 1)
[31]. The dynamic data for each ROI were exported to
Microsoft Excel to evaluate renal function, which was rep-
resented as renograms depicting percentage of injected ac-
tivity (%IA). The fractional uptake rate (FUR), which
constitutes a measure of renal clearance, was calculated as
described previously [30]. In brief, the FUR is defined as
the fractional uptake of a tracer in the blood by an organ
as a function of time. FUR is calculated as FUR =
P(0)*(kl + kr)/[ID], where P(0) (counts per second) is the
magnitude of the plasma clearance curve P(t) at time zero,
which is obtained by back extrapolation using a mono-ex-
ponential fitting of the data to P(t), and kl and kr are
the slopes of the linear uptake (LU) segment of the Patlak-
Rutland (PR) plots for the left and right kidneys [32].
Histopathological analysis
At the end of the 3-month follow-up, mice were eutha-
nized by cervical dislocation. Kidneys were removed,
fixed in 4 % formalin, and embedded in paraffin. Histo-
logical sections were cut on a microtome and stained
with hematoxylin-eosin (H.E.) and periodic acid-Schiff
reagent (PAS). Renal damage was evaluated qualitatively
according to a previously described scale [16, 17], ran-
ging from no histological damage to severe histological
damage based on htethe assessment criteria listed in
Table 1. Whenever one of the criteria (e.g., tubular dila-
tation, cell-rich infiltrate) was evident, the damage was
scored in the respective highest damage score.
Fig. 1 Image file at 12-min examination. Time activity curves were
obtained by standard manual region of interest (ROI) analyses of the
whole body (3), kidneys (4 and 5), kidney backgrounds (6 and 7),
and site of injection (1)
Table 1 Histological assessment criteria for renal damage
(adapted from Rolleman et. al, EJNMMI 2007 [16])
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Statistical analysis
Data are expressed as mean ± SEM. Normality was
tested with the Shapiro-Wilk test. The paired or un-
paired t test (two-sided) was used to test statistical sig-
nificant differences of normally distributed results, and
the Mann-Whitney-U-test was used when normality re-
quirements were not met, with p < 0.05 considered in
both cases as statistically significant.
Results
Identification of nephrotoxic activity of [177Lu]-DOTATATE
Figure 2 illustrates the mean renograms for groups 1–4
at day 65. Relative to findings in the baseline group, the
peak %IA amplitude was unchanged in group 1, in-
creased in groups 2 and 3, and decreased in group 4,
which had received the highest [177Lu]-DOTATATE ac-
tivity. The time to peak %IA was likewise unchanged in
group 1, delayed in groups 2 and 3, and shortened in
group 4. The excretion capacity, assessed from the de-
cline in %IA between peak and 10 min, was most im-
paired in group 3.
FUR values decreased significantly in all therapy
groups at day 9 as compared to the baseline group
(p < 0.01) (Fig. 3). During subsequent follow-up, FUR
increased in group 1 (10 MBq), showing no signifi-
cant difference at day 65 as compared to baseline
values (11.2 ± 0.5 %IA/min vs. 11.0 ± 0.4 %IA/min).
Similar findings were seen in group 2 (20 MBq). FUR
values in groups 3 and 4 likewise recovered during
initial follow-up but had significantly declined in a
dose-dependent manner on the final scintigraphy day,
when group 3 FUR was 8.9 ± 0.6 %IA/min (p < 0.05)
and group 4 FUR was 6.0 ± 0.8 %IA/min (p < 0.01).
Histological sections at day 65 (Fig. 4) exhibited evi-
dence for increasing renal damage (tubular dilatation
and basal membrane thickening) with increasing PRRT
activity. In particular, pronounced to severe renal injury
in terms of glomeral shrinkage and tubular damage was
most evident in the 40 and 65 MBq radiotherapy groups.
However, no signs of pronounced necrosis were seen in
any therapy group.
The synopsis of renogram, FUR analysis, and histo-
pathological changes illustrated comprehensive renal
damage at the two highest activities. We selected group
3 [177Lu]-DOTATATE activity (40 MBq) for the evalu-
ation of pharmaceutical nephroprotection after enalapril
treatment as a trade-off between producing a measure-
able defect and potentially excessive kidney failure.
Evaluation of pharmaceutical nephroprotection
Mean renogram curves of enalapril-treated and control
mice from day 9 after PRRT until day 86 are available as
Additional file 1. Figure 5 shows the mean renogram
curves of the enalapril and control groups at day 86
compared to baseline renograms prior to PRRT. The
relatively elevated peaks in the mean renograms of the
enalapril group and the steeper slopes relative to the
control group are consistent with the preservation of
renal function, although the curves are moderately im-
paired compared to baseline.
We observed significantly decreased FUR values relative
to baseline in both PRRT groups at day 9 (p < 0.01) (Fig. 6).
At subsequent follow-up, FUR values tended to increase
in the enalapril group, becoming non-significantly differ-
ent from baseline (12.5 ± 0.3 %IA/min) at day 86 for enala-
pril treatment (11.8 ± 0.5 %IA/min), indicating rescue of
renal function. In contrast, the mean FUR measurements
Fig. 2 Renograms at follow-up examination at day 65. Renal dysfunction is reflected by decreased uptake and slope. Error bars not shown for clarity
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Fig. 3 FUR values at baseline and days 9, 23, 44, and 65 in the first block of the study. All therapy groups exhibit decreased FUR at day 9. Increasing
FUR values are obtained in the 10 and 20 MBq groups until day 65, whereas FUR in the 40 and 65 MBq groups remains significantly decreased
Fig. 4 Histological sections (PAS) at day 65 in the first block of the study. With increasing therapy activities, renal damage gets more pronounced
in terms of glomerular shrinkage (arrow), basal membrane thickening and tubular dilation (double arrow)
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in the control group remained significantly reduced rela-
tive to baseline at days 9, 23, 44, 65, and at day 86, when
the FUR was 9.3 ± 0.5 %IA/min (p < 0.01).
Histological sections at day 86, as seen in Fig. 7, exhibit
renal damage manifesting in tubular dilatation, thickening
of the basal membrane, and glomeral shrinkage in the
control group (pronounced to severe damage). There are no
signs of histological damage visible in enalapril-treated mice.
Non-therapy control group
No relevant changes in mean renograms were observ-
able during the follow-up period of 3 months (data not
Fig. 5 Renogram curves in the second part of the study at day 86. Both mean renogram curves in enalapril and control groups present a decreased
peak value as compared to baseline, however, more pronounced in the control group. The flattening slopes indicate relatively higher renal damage in
the water-treated control group as compared to the enalapril group. Regular slope in the enalapril group reveals normal renal excretion capacity
Fig. 6 FUR values at baseline and days 9, 23, 44, 65, and 86 in the second block of the study. FUR remains relatively stable in the no PRRT control
group. Decreased FUR values are presented in the PRRT groups a day 9. However, values in the enalapril group increase until day 86, whereas
values in the water-treated control group remain significantly reduced as compared to baseline
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shown). Mean FUR values at the final day of follow-up re-
vealed significant differences as compared to the water-
treated control group, whereas no significant differences
were measured in comparison to enalapril-treated mice
underlining the nephroprotective effect of these treatment
options (mean FUR after 3 months: 11.9 ± 0.8 %IA/min;
p < 0.05 vs. water; p = n.s. vs. enalapril) (see Fig. 6).
Histological sections did not reveal any renal damage in
this group.
Discussion
In clinical practice, the acceptable limit for kidney ra-
diation during PRRT (23 Gy) is based upon findings
with external beam radiation [33]. Mitigation of
nephrotoxicity would offer the possibility to increase
the radioactivity per cycle of PRRT and/or increase
the number of cycles, to the benefit of NET patients.
With this in mind, we investigated the nephroprotec-
tive characteristics of enalapril treatment in a mouse
model of [177Lu]-DOTATATE therapy-induced ne-
phropathy based upon encouraging results in studies
based on external beam radiation [12, 24, 25].
Renal laboratory parameters such as blood urea nitro-
gen (BUN) and creatinine were unaffected in rats
6 weeks after PRRT, despite the occurrence of histo-
logical proven nephrotoxicity [34]. However, other stud-
ies are contradictory and describe an accordance of
blood urea nitrogen and creatinine levels with kidney
damage in mice, which was, however, true only in pro-
nounced radiation-induced kidney damage [35, 36].
Therefore, we implemented MAG3 scintigraphy in order
to quantify renal function in the course of treatments.
MAG3 scintigraphy offers a non-invasive and individual
evaluation of renal function in the course of radiation
nephropathy [30]. Firstly, we determined the activity of
[177Lu]-DOTATATE-induced nephrotoxic effects mea-
sured with MAG3 scintigraphy in mice. The establish-
ment of a mouse model is of great importance, as the
availability of diverse immune-deficient mouse models
could deliver more insight into immunological pro-
cesses of radiation nephropathy in prospective studies.
Renograms proved to be highly variable in mice, such
that we decided to test the FUR quantitative ap-
proach, which provided a more sensitive index of the
extent of renal failure at day 65. The FUR approach
also showed clearly the temporal dynamics of altered
renal function, which included a transient decline at
day 9 irrespective of the [177Lu]-DOTATATE activity,
subsequent recovery at days 23 and 44, and the emer-
gence of a clearly activity-dependent nephrotoxic ef-
fect at day 65. However, the transient decline evident
at day 9 even in the present group of mice receiving
only 10 MBq [177Lu]-DOTATATE suggests the oc-
currence of acute toxicity at an activity far below that
required to provoke chronic renal failure, which takes
several months to develop.
The superiority of FUR to renograms is substanti-
ated by the findings of our group in a mouse model
of ischemia-reperfusion injury [30]. We settled upon
40 MBq [177Lu]-DOTATATE, so as to obtain a dis-
tinct and reproducible impairment of renal function
in the subsequent nephroprotection treatment arm of
the study, without risking morbidity due to complete
renal failure.
As noted above, the most common intervention for
reducing kidney irradiation from radiolabeled somato-
statin analogues is to competitively block their tubular
reabsorption by co-infusion of basic amino-acids. Alter-
nately, it might be possible to interfere with radiation-
induced pathological processes leading to fibrosis and
apoptosis. For example, the anti-oxidant amifostine atten-
uated renal damage in rats by the reduction of oxidative
stress arising from [177Lu]-DOTATATE treatment [37].
Dual therapy with amino acids and anti-oxidants might
have an additive or super-additive (synergistic) effect in
rescuing renal function following internal irradiation, but
this approach has yet to be investigated. Given that the
RAAS pathway seems to play a central role in the
Fig. 7 Histological sections (PAS) at day 86 in the second block of the study. Renal damage in terms of glomerular shrinkage (arrow), thickening
of the basal membrane, and tubular dilation (double arrow) is presented in the control group (pronounced to severe renal damage). No signs of
renal damage in the enalapril group
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pathophysiology of radiation-induced nephropathy
[21], pharmaceutical intervention and modification of
the RAAS should also present avenues for the mitiga-
tion of renal damage during PRRT. Enalapril is of
proven efficacy in reducing injury in therapies leading
to comparable patterns of renal damage as are pro-
voked by [177Lu]-DOTATATE therapy. In particular,
enalapril prevented radiation nephritis and fibrosis in
rats after external beam radiation [24, 38]. The underlying
mechanism of this effect of enalapril is uncertain; however,
changes in glomerular capillary pressure and a reduction
of circulating angiotensin II are discussed to be respon-
sible for the mitigation of renal damage [24].
In our study, enalapril treatment likewise substantially
rescued renal function, which was restored to baseline
levels at day 86, as measured by FUR, and as also seen by
renogram analysis. Furthermore, renal histology was en-
tirely normal in the enalapril-treatment group, providing
further support for the potential clinical use of enalapril in
reducing functional and histopathological changes in the
kidney after PRRT with [177Lu]-DOTATATE.
We consistently found that kidney function was reduced
in the acute phase 1 week after [177Lu]-DOTATATE ther-
apy, for the entire range of activities as depicted in signifi-
cantly decreased FUR values. This seems to be the first
such report after PRRT in mice. We did not obtain histo-
logical sections at day 9, and so we are unable to ascertain
if this initial decline in renal function is associated with
structural alterations. The functional impairment evoked
by 40 MBq at day 9 was not reduced by enalapril treat-
ment and persisted in the water-treated control group
until day 86. However, mean FUR scores had normalized
by day 86 in enalapril-treated mice. As data on pharmaco-
logical nephroprotection in mice after PRRT is still miss-
ing, the applied dose of enalapril was based upon results
of previously published studies dealing with other scien-
tific questions. A dose-response analysis would have been
more accurate and will be performed in upcoming studies.
Functional data was based on MAG3 scintigraphy
within a period of almost 3 months. A rat study has shown
that MAG3 is a highly sensitive marker for the detection
of renal damage after [177Lu]-DOTATATE therapy within
a follow-up period of almost 4 months [39]. However, in a
study dealing with folate-receptor-targeted therapy kidney
damage was accurately measured using [99 m]-DMSA
SPECT. This enabled an analysis of the correlation of
kidney dose and kidney damage, which might offer an
even more enhanced monitoring of kidney damage
[35]. A previous study of our workgroup demon-
strated that MAG3 scintigraphy with one single head
of a triple-headed camera was accurate enough to de-
pict renal function. However, there are several studies
using a dedicated dynamic animal-SPECT [39, 40].
Studies comparing these different methods are
missing, but, e. g., in terms of ROI vs. VOI analysis
and thus accuracy SPECT is likely to be superior.
Nevertheless, with the aid of renogram analysis and
the calculation of the FUR, persistent impairment of
renal function in mice after [177Lu]-DOTATATE
therapy activity of at least 40 MBq is measurable by
scintigraphy and was verified by histology.
Conclusions
Treatment with enalapril for 3 months after radio-
therapy with [177Lu]-DOTATATE mitigated renal
damage in mice. Enalapril treatment could be an add-
itional option for ameliorating the dose-limiting effects of
radiation-induced kidney damage, thus allowing applica-
tion of more effective therapy activities. Due to a moder-
ate side effect profile and the applicability in patients with
renal risk factors like hypertension and diabetes,
which aggravate the nephrotoxicity of PRRT [41],
enalapril treatment might be a promising therapy.
Additional file
Additional file 1: Renogram curves for enalapril treatment in the
second part of the study. (TIF 3031 kb)
Abbreviations
ACE, angiotensin-converting-enzyme; FUR, fractional uptake rate; HE,
hematoxylin-eosin; MAG3, [99mTc]-mercaptoacetyltriglycine; NET,
neuroendocrine tumor; PAS, periodic acid-Schiff reagent; PRRT, peptide
receptor radionuclide therapy; RAAS, renin-angiotensin-aldosterone-system;
ROI, region of interest
Funding
This study was funded by the FöFoLe program of the medical faculty of the
Ludwig-Maximilians-University of Munich.
Authors’ contributions
HI and AH contributed to the study design, preparation of the study,
conducting of the measurements, analyzing of the data, drafting of the
manuscript, and critical revision of the manuscript. HW, FG, CW, TH, AT, JS,
and PC contributed to the preparation of the study, conducting of the
measurements, and analyzing of the data. MH and PB contributed to the
study design, drafting of the manuscript, and critical revision of the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval
All animal experiments were conducted in accordance with institutional
guidelines and approved by the ethics committee and Administrative Panel
on Laboratory Animal Care (Government of Upper Bavaria, Germany;
reference number 55.2-1-54-2531-136-09).
Author details
1Department of Nuclear Medicine, University of Munich, Munich, Germany.
2Department of Surgery, Campus Großhadern, University of Munich, Munich,
Germany. 3Department of Biomedical Imaging and Image-Guided Therapy,
Division of Nuclear Medicine, University of Vienna, Vienna, Austria. 4Institute
of Pharmacy and Molecular Biotechnology, University of Heidelberg,
Heidelberg, Germany.
Ilhan et al. EJNMMI Research  (2016) 6:64 Page 8 of 9
Received: 7 May 2016 Accepted: 4 August 2016
References
1. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols
LK, et al. Overview of results of peptide receptor radionuclide therapy with
3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62S–6.
2. Haug AR, Bartenstein P. Gastroenteropancreatic neuroendocrine tumors:
diagnosis and therapy in nuclear medicine. Internist (Berl). 2012;53:161–6.
3. Bushnell Jr DL, O’Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem
E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J
Clin Oncol. 2010;28:1652–9.
4. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al.
Response, survival, and long-term toxicity after therapy with the
radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized
neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.
5. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The
clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in
the treatment of neuroendocrine tumours: a clinical phase II study. Ann
Oncol. 2001;12:941–5.
6. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP,
et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,
Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.
7. Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of
radiopeptide 177Lu-octreotate and capecitabine therapy of progressive
disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;
38:302–11.
8. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al.
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-
DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;
31:1038–46.
9. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-
diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to
pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res.
1997;57:659–71.
10. de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al.
Megalin is essential for renal proximal tubule reabsorption of (111)In-
DTPA-octreotide. J Nucl Med. 2005;46:1696–700.
11. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with
90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552–4.
12. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A
new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC
internal radiotherapy. Am J Kidney Dis. 2001;37:847–51.
13. Stoffel MP, Pollok M, Fries J, Baldamus CA. Radiation nephropathy after
radiotherapy in metastatic medullary thyroid carcinoma. Nephrol Dial
Transplant. 2001;16:1082–3.
14. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al.
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC:
relevance of kidney volume and dose rate in finding a dose-effect
relationship. J Nucl Med. 2005;46 Suppl 1:99S–106.
15. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al.
Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439–47.
16. Rolleman EJ, Krenning EP, Bernard BF, de Visser M, Bijster M, Visser TJ, et al.
Long-term toxicity of [(177)Lu-DOTA (0), Tyr (3)]octreotate in rats. Eur J Nucl
Med Mol Imaging. 2007;34:219–27.
17. Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning EP, et al. From
outside to inside? Dose-dependent renal tubular damage after high-dose
peptide receptor radionuclide therapy in rats measured with in vivo
(99 m)Tc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm.
2007;22:40–9.
18. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et
al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl
Med. 1996;37:1388–92.
19. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al.
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association
with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging.
2003;30:207–16.
20. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and
effective inhibition of renal uptake of radiolabelled octreotide by a
combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;
30:9–15.
21. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003;23:
486–99.
22. Cohen EP, Fish BL, Moulder JE. The renin-angiotensin system in
experimental radiation nephropathy. J Lab Clin Med. 2002;139:251–7.
23. Cohen EP, Fish BL, Moulder JE. Treatment of radiation nephropathy with
captopril. Radiat Res. 1992;132:346–50.
24. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with
ACE inhibitors. Int J Radiat Oncol Biol Phys. 1993;27:93–9.
25. Juncos LI, Carrasco Duenas S, Cornejo JC, Broglia CA, Cejas H. Long-term
enalapril and hydrochlorothiazide in radiation nephritis. Nephron. 1993;64:
249–55.
26. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising
conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu
at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917–20.
27. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion
JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-
DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.
28. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, et al. Combined AGE
inhibition and ACEi decreases the progression of established diabetic
nephropathy in B6 db/db mice. Kidney Int. 2006;70:507–14.
29. Roberts J, Chen B, Curtis LM, Agarwal A, Sanders PW, Zinn KR. Detection of
early changes in renal function using 99mTc-MAG3 imaging in a murine
model of ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2007;293:
F1408–12.
30. Herrler T, Wang H, Tischer A, Bartenstein P, Jauch KW, Guba M, et al.
[99mTc]MAG3 scintigraphy for the longitudinal follow-up of kidney function
in a mouse model of renal ischemia-reperfusion injury. EJNMMI Res. 2012;2:2.
31. Herrler T, Tischer A, Meyer A, Feiler S, Guba M, Nowak S, et al. The intrinsic
renal compartment syndrome: new perspectives in kidney transplantation.
Transplantation. 2010;89:40–6.
32. Rutland M, Que L, Hassan IM. “FUR”—one size suits all. Eur J Nucl Med.
2000;27:1708–13.
33. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al.
Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol
Phys. 1991;21:109–22.
34. Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, et al. Toxicity and
dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer. 2001;
94:873–7.
35. Haller S, Reber J, Brandt S, Bernhardt P, Groehn V, Schibli R, et al. Folate
receptor-targeted radionuclide therapy: preclinical investigation of anti-
tumor effects and potential radionephropathy. Nucl Med Biol. 2015;42:770–9.
36. Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, Koster U, Bernhardt
P, et al. Contribution of Auger/conversion electrons to renal side effects
after radionuclide therapy: preclinical comparison of (161)Tb-folate and
(177)Lu-folate. EJNMMI Res. 2016;6:13.
37. Rolleman EJ, Forrer F, Bernard B, Bijster M, Vermeij M, Valkema R, et al.
Amifostine protects rat kidneys during peptide receptor radionuclide
therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging.
2007;34:763–71.
38. Molteni A, Moulder JE, Cohen EP, Fish BL, Taylor JM, Veno PA, et al.
Prevention of radiation-induced nephropathy and fibrosis in a model of
bone marrow transplant by an angiotensin II receptor blocker. Exp Biol Med
(Maywood). 2001;226:1016–23.
39. Melis M, de Swart J, de Visser M, Berndsen SC, Koelewijn S, Valkema R, et al.
Dynamic and static small-animal SPECT in rats for monitoring renal function
after 177Lu-labeled Tyr3-octreotate radionuclide therapy. J Nucl Med. 2010;
51:1962–8.
40. Jouret F, Walrand S, Parreira KS, Courtoy PJ, Pauwels S, Devuyst O, et al.
Single photon emission-computed tomography (SPECT) for functional
investigation of the proximal tubule in conscious mice. Am J Physiol Renal
Physiol. 2010;298:F454–60.
41. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al.
Long-term evaluation of renal toxicity after peptide receptor radionuclide
therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated
risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.
Ilhan et al. EJNMMI Research  (2016) 6:64 Page 9 of 9
